Mark Plavsic - 25 Jan 2022 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Reporting relationship: Chief Technical Officer
Issuer ticker: FATE
Reported as of: 25 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jan 2022, 15:37:25 UTC
Prior SEC filing: 22 Nov 2021
Next SEC filing: 06 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Cindy Tahl, Attorney-in-Fact

Key filing fact

Mark Plavsic filed Form 4 for FATE THERAPEUTICS INC (FATE) on 27 Jan 2022.

Key facts

This page summarizes Mark Plavsic's Form 4 filing for FATE THERAPEUTICS INC (FATE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Jan 2022, 15:37.

Change

Previous filing in this sequence was filed on 22 Nov 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

FATE transaction

Common Stock

Award

Transaction value: $0
Shares: +33,302
Change %: +34%
Price: $0.000000
Shares after: 130,842
Date: 25 Jan 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FATE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +53,058
Change %
Price: $0.000000
Shares after: 53,058
Date: 25 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 53,058
Exercise price: $39.87
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Award of restricted stock units that vest with respect to 1/4th of the underlying shares on each of January 8, 2023, January 8, 2024, January 8, 2025 and January 8, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date.

Footnote F2

The shares subject to this option vest in 48 equal month installments beginning on February 1, 2022 such that this option will be fully exercisable on January 1, 2026, subject to the Reporting Person's continued service with the Issuer as of each such date.